Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease.

Britt ChristensenD MicicP R GibsonA YarurE BellaguardaP CorselloJ N GaetanoJ KinnucanV L RaoS ReddyS SinghJ PekowD T Rubin

Published in: Alimentary pharmacology & therapeutics (2018)

Vedolizumab treatment in patients with PSC and IBD did not improve liver biochemistry but was associated with improvement in bowel disease and a favourable safety profile.

Keyphrases

ulcerative colitis
patients with inflammatory bowel disease
locally advanced
smoking cessation